Oregon is currently home to 1206 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Portland, Eugene, Medford and Clackamas. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
06/04/2025
Locations: Saint Alphonsus Cancer Care Center-Baker City, Baker City, Oregon
Conditions: Breast Cancer
Register for Updates
Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study
NCT04331769
Recruiting
Prospective, randomized, open-label, international, multi-center clinical study to evaluate the safety and efficacy of the AccuCinch Ventricular Restoration System in patients with heart failure and reduced ejection fraction (HFrEF).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Providence St. Vincent Medical Center, Portland, Oregon
Conditions: Heart Failure With Reduced Ejection Fraction (HFrEF), Dilated Cardiomyopathy
Register for Updates
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT03897881
Recruiting
The purpose of this study is to assess whether postoperative adjuvant therapy with mRNA-4157 and pembrolizumab improves recurrence free survival (RFS) compared to pembrolizumab alone in participants with complete resection of cutaneous melanoma and a high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Providence Cancer Institute, Portland, Oregon
Conditions: Melanoma
Register for Updates
MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma
NCT03699995
Recruiting
This trial studies how well MoleMapper, Visiomed, and confocal microscopy work in screening participants for melanoma. Analyzing images (photographs) made with three different portable imaging systems may be as good as a visit to a dermatologist's office for finding melanomas before they can spread.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
06/04/2025
Locations: Sancy Leachman, Portland, Oregon
Conditions: Cutaneous Melanoma, Melanocytic Nevus, Skin Carcinoma
Register for Updates
Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone and in Combination in Participants With Solid Tumors
NCT03313778
Recruiting
The purpose of this study is to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone and in combination in participants with solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/04/2025
Locations: Providence Portland Medical Center, Portland, Oregon
Conditions: Solid Tumors
Register for Updates
A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06879041
Recruiting
The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Research Site, Portland, Oregon
Conditions: Metastatic Castration-Resistant Prostate Cancer
Register for Updates
A Study to Evaluate Mazdutide Compared With Placebo in Participants With Alcohol Use Disorder
NCT06817356
Recruiting
The objective of this proof-of-concept study to evaluate mazdutide in participants with alcohol use disorder (AUD). For any individual participant, the maximum duration of study participation is approximately 36 weeks, including screening and posttreatment follow-up.
Gender:
ALL
Ages:
Between 21 years and 65 years
Trial Updated:
06/03/2025
Locations: Summit Headlands, Portland, Oregon
Conditions: Alcohol Use Disorder
Register for Updates
A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
NCT06672055
Recruiting
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19). In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain)... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Velocity Clinical Research - Grants Pass, Grants Pass, Oregon
Conditions: SARS-CoV2, COVID-19
Register for Updates
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
NCT05957367
Recruiting
This is a Phase 1/2, multicenter, open-label (unless otherwise specified in a combination-specific module) study of inlexisertib in combination with anticancer therapies. Modules within the master protocol are defined according to different combinations of inlexisertib with other anticancer agents.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Oregon Health & Science University, Portland, Oregon
Conditions: GIST
Register for Updates
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
NCT05680597
Recruiting
This project will determine the feasibility and efficacy of remote assessment and treatment of balance disorders in people with Parkinson's disease.
Gender:
ALL
Ages:
Between 55 years and 85 years
Trial Updated:
06/03/2025
Locations: Oregon Health Science University, Portland, Oregon
Conditions: Parkinson Disease
Register for Updates
Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
NCT05654506
Recruiting
The purpose of this research is to study the safety and efficacy of daratumumab in inducing complete or partial remission in people with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/03/2025
Locations: Oregon Health and Science University, Portland, Oregon
Conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
06/03/2025
Locations: Providence St Vincent Med Center, Portland, Oregon
Conditions: Relapsing Multiple Sclerosis
Register for Updates